A Case Study to Assess a Brightening Skincare Regimen in Patients With Bothersome Skin Dark Spots
A Single-Center, Open-Label Case Study to Assess a Brightening Skincare Regimen in Patients With Bothersome Skin Dark Spots
This 12- week, single-center, open-label case study is being conducted to assess the efficacy and tolerance of a brightening skincare regimen comprised of a facial wash, brightening serum, brightening exfoliating pads, face cream and sunscreen by healthy females with clinically determined mild to moderate Post-inflammatory hyperpigmentation (PIH).
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
At Visit 1, prior to the start of the study, prospective subjects will be screened for eligibility requirements based on inclusion and exclusion criteria and will be enrolled into the study. Prospective subjects will be given an Institutional Review Board (IRB)-approved Informed Consent Form (ICF) and photography release form (PRF) to read and sign. Subjects will be provided the pre-washout skincare products, written usage instructions, and a daily diary.
At Baseline (Visit 2), subjects will have their face evaluated by a board-certified dermatology for clinical efficacy parameters (skin tone evenness, overall appearance, and PIH) and evaluate tolerability (Erythema, edema, and dryness) parameters. Subjects will then rate the Itching, Burning, and Stinging and complete a self-assessment questionnaire (SAQ). A clinical staff will take standardized clinical photographs using VISIA® Imaging.
At Visit 3, 4, 5, and 6 dermatologist clinical efficacy and tolerability, as well as subject tolerability assessments will be performed, followed by clinical photography. Subjects will complete an SAQ before the visit ends.
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- 適用できない
連絡先と場所
研究場所
-
-
Texas
-
The Woodlands、Texas、アメリカ、77380
- REVE Dermatology and Aesthetics
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Female (biological), 25 to 55 years of age
- Having Fitzpatrick skin type I-VI (refer to Appendix I: Fitzpatrick Skin Type)
- Having mild to moderate Post-Inflammatory Hyperpigmentation as identified as a grade 2 or 3 on the 5-point Investigator Global Assessment Scale [ 0 = clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate, 4 = Severe]
- Having active Post-Inflammatory Hyperpigmentation due to blemish-prone skin with no active breakouts within the last 3 months
- Having active PIH due to sun exposure, rosacea, and procedures
- Self-perceived very bothersome hyperpigmentation (darkening), including spots, on the global face
- In good general health (physical, mental, and social well-being, not merely the absence of disease/infirmity), according to subject self-report.
Exclusion Criteria:
- Breastfeeding, pregnancy, or planning to become pregnant
- Having been diagnosed with known allergies to skin care products
- Having a known reactivity to tranexamic acid, niacinamide, sunflower seed, coconut, rosemary, barley, goji, sandalwood, licorice root, radish root, beeswax, yeast, ascorbic acid, tetrahexyldecyl ascorbate, and/or any of the ingredients in the study products
- Having a health condition and/or pre-existing or dormant dermatologic disease on the face
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Brightening Serum and Brightening Pads
From baseline to week 12, subjects will apply a Brightening Serum (2x daily), and brightening pads 3 times per week in the evening only (Monday, Wednesday, Friday) or (Tuesday, Thursday, Saturday). |
From baseline to week 12, subjects will use a Brightening Facial Wash (2x daily), Facial Moisturizer (2x daily), and broad-spectrum sunscreen moisturizer SPF 50 (morning only). Participants were asked to apply the sunscreen if sun exposure was more than 30 minutes per day. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Improvement of Clinical Efficacy Parameters at 2, 4, 8, and 12 weeks versus Baseline
時間枠:Weeks 2, 4, 8, and 12 compared to baseline
|
A board-certified dermatologist will grade skin tone evenness, overall appearance, and PIH at baseline and at weeks 2, 4, 8, and 12. Skin tone evenness and overall appearance will be graded using the modified Griffiths 10-point scale (0 = Even healthy skin color; 9 = Uneven, discolored appearance), while PIH will be measured using a 4-point investigator global assessment scale (0 = clear, 1 = mild, 2 = moderate, and 3 = severe). Higher scores indicate greater severity of the respective skin condition, where a decrease in score indicates an improvement. |
Weeks 2, 4, 8, and 12 compared to baseline
|
|
Measurement of subject self assessment questionnaire
時間枠:Baseline, weeks 2, 4, 8, and 12
|
Subjects will complete a self-assessment questionnaire which will consist of a series of questions related to subjects' evaluation of product efficacy and attributes. Subjects are asked to rate based on a scoring system of the following: from 5 (completely agree) to 1 (completely disagree). The best outcome is to Completely Agree with the statement / question being asked. |
Baseline, weeks 2, 4, 8, and 12
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Lack of Significant Increase in Objective Tolerability Parameters at weeks, 2, 4, 8, 12 compared to Baseline
時間枠:Baseline, weeks 2, 4, 8, and 12
|
Clinical grading of Objective Irritation Parameters (Erythema, Edema, and Dryness) evaluated by investigator and subject reporting of Subjective Irritation Parameters (Burning, Stinging, Itching) using a 4 point scale: 0 = None to 3 = Severe. A change in scores or lack of significant change at week 2, 4, 8 and 12 compared to Baseline indicates tolerability/safety of the test material. A lower score indicating a better outcome. |
Baseline, weeks 2, 4, 8, and 12
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- RS-2025-05
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。